Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

J. Goldstein, B. Tran, J. Ensor, P. Gibbs, H. L. Wong, S. F. Wong, E. Vilar, J. Tie, R. Broaddus, S. Kopetz, J. Desai, M. J. Overman

Research output: Contribution to journalArticlepeer-review

211 Scopus citations


Background: The microsatellite instability-high (MSI-H) phenotype, present in 15% of early colorectal cancer (CRC), confers good prognosis. MSI-H metastatic CRC is rare and its impact on outcomes is unknown. We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC). Patients and methods: A retrospective review of 55 MSI-H metastatic CRC patients from two institutions, Royal Melbourne Hospital (Australia) and The University of Texas MD Anderson Cancer Center (United States), was conducted. Statistical analyses utilized Kaplan–Meier method, Log-rank test, and Cox proportional hazards models. Results: Median age was 67 years (20–90), 58% had poor differentiation, and 45% had stage IV disease at presentation. Median overall survival (OS) from metastatic disease was 15.4 months. Thirteen patients underwent R0/R1 metastatectomies, with median OS from metastatectomy 33.8 months. Thirty-one patients received first-line systemic chemotherapy for metastatic disease with median OS from the start of chemotherapy 11.5 months. No statistically significant difference in progression-free survival or OS was seen between fluoropyrimidine, oxaliplatin, or irinotecan based chemotherapy. BRAF V600E mutation was present in 14 of 47 patients (30%). BRAF V600E patients demonstrated significantly worse median OS; 10.1 versus 17.3 months, P = 0.03. In multivariate analyses, BRAF V600E mutants had worse OS (HR 4.04; P = 0.005), while patients undergoing metastatectomy (HR 0.11; P = <0.001) and patients who initially presented as stage IV disease had improved OS (HR 0.27; P = 0.003). Conclusions: Patients with MSI-H metastatic CRC do not appear to have improved outcomes. BRAF V600E mutation is a poor prognostic factor in MSI-H metastatic CRC.

Original languageEnglish (US)
Pages (from-to)1032-1038
Number of pages7
JournalAnnals of Oncology
Issue number5
StatePublished - May 2014


  • BRAF V600E mutation
  • chemotherapy
  • colorectal cancer
  • metastatectomy
  • microsatellite instability-high
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)'. Together they form a unique fingerprint.

Cite this